• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Orthofix Medical Inc.

    5/30/25 4:33:26 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care
    Get the next $OFIX alert in real time by email
    SD 1 ofix_form_sd-ye2024.htm SD SD

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM SD

     

     

    Specialized Disclosure Report

     

    img196134758_0.jpg

     

    ORTHOFIX MEDICAL INC.

    (Exact name of Registrant as specified in its charter)

     

     

    Delaware

     

    0-19961

     

    98-1340767

     

    (State or other jurisdiction of incorporation)

     

    (Commission File Number)

     

    (IRS Employer Identification No.)

     

     

     

    3451 Plano Parkway,

    Lewisville, Texas

     

    75056

    (Address of principal executive offices)

     

    (Zip Code)

     

     

    J. Andrés Cedrón

    Chief Legal Officer

    (214) 937-2000

     

    (Name, and telephone number, including area code, of the

    person to contact in connection with this report)

     

    Check the appropriate box below to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1, 2024 to December 31, 2024

     

     


     

    Section 1 – Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    This Form SD of Orthofix Medical Inc. (the "Company") is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2024 to December 31, 2024.

    A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD, and is publicly available under the "Investors" heading of the Company’s website, www.orthofix.com. References to the Company’s website are provided for convenience only, and its contents are not incorporated by reference into this Form SD, the Conflict Minerals Report, nor are they deemed filed with the U.S. Securities and Exchange Commission.

    Item 1.02 Exhibit

    A copy of the Company’s 2024 Conflict Minerals Report is filed as Exhibit 1.01 attached to this Form SD.

    Section 2 – Exhibits

    Item 2.01 Exhibits

    The following exhibit is filed as part of this report.

     

    Exhibit No.

     

    Description of Exhibit

       1.01

     

    Conflict Minerals Report of Orthofix Medical Inc.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    Orthofix Medical Inc.

    (Registrant)

     

    By:

     

     

    /s/ J. ANDRÉS CEDRÓN

     

     

    J. Andrés Cedrón

    Chief Legal Officer

     

     

     

     

     

    Date: May 30, 2025

     

     


    Get the next $OFIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OFIX

    DatePrice TargetRatingAnalyst
    1/22/2025$24.00Buy
    Canaccord Genuity
    11/8/2024$18.00 → $24.00Hold → Buy
    Stifel
    5/8/2024$15.00 → $20.00Neutral → Buy
    ROTH MKM
    10/20/2023$12.00Neutral
    ROTH MKM
    9/12/2023Buy → Neutral
    BTIG Research
    9/12/2023Buy → Hold
    Stifel
    7/19/2023$27.00Buy
    BTIG Research
    3/4/2022$41.00 → $45.00Hold → Buy
    Stifel
    More analyst ratings

    $OFIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Orthofix with a new price target

      Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00

      1/22/25 7:47:50 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix upgraded by Stifel with a new price target

      Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously

      11/8/24 8:23:19 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix upgraded by ROTH MKM with a new price target

      ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously

      5/8/24 6:31:28 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bazaar Alan Lee bought $24,570 worth of shares (2,250 units at $10.92), increasing direct ownership by 8% to 30,983 units (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      6/5/25 5:11:05 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Amendment: Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

      4/A - Orthofix Medical Inc. (0000884624) (Issuer)

      5/14/25 4:34:50 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • President & CEO Calafiore Massimo bought $125,400 worth of shares (10,000 units at $12.54), increasing direct ownership by 4% to 234,603 units (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/12/25 7:14:09 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the global commercial launch of the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate represents the first commercially available device in the U.S. with a patented design for use in the TBT procedure to provide a limb preservation treatment option for addressing bony or soft tissue deformities or defects, such as diabetic ulcers. "I have been using the TrueLok Elevate System in my practice to treat patients with ulcers and other ischemic conditions and am pleased by the results I have observed so far," said Victor Anciano, M.D., a foot and ankle surgeon in Louisville,

      6/17/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Reports First Quarter 2025 Financial Results

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

      5/6/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual Meeting

      Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port

      4/16/25 8:00:00 AM ET
      $AVID
      $FOR
      $HSON
      $IGT
      Computer Software: Prepackaged Software
      Technology
      Real Estate
      Finance